24 research outputs found
Impact of blood glucose variability on carotid artery intima media thickness and distensibility in type 1 diabetes mellitus
Aims. Diabetes mellitus is characterized by structural and functional alterations of the large- and medium-size arteries. Whether blood glucose variability, i.e. the glycemic oscillations occurring during the 24-h period, represents a risk factor for vascular alterations additional to and independent on HbA1c in type 1 diabetes mellitus is still undefined. The present study was carried out with the aim at investigating the impact of different measures of blood glucose variability on arterial structure and function. We studied 17 non-complicated type 1 diabetic patients (11 males, six females) with an age of 40.8 ± 7.6 years (mean ± SD). In each patient, 24-h glucose profile was obtained by continuous glucose monitoring system and glucose variability was expressed as mean ± SD of 24-h blood glucose levels, mean amplitude of glycemic excursions and postprandial hyperglycemic spikes. Arterial structure and function was measured as carotid IMT and stiffness. Major findings. The different approaches to assessing blood glucose variability well correlated between and with HbA1c. Carotid IMT and stiffness showed significant correlations with age, blood pressure, heart rate and daily insulin intake but a non- significant correlation with blood glucose variability. Principal conclusion. Thus, in type 1 diabetes mellitus, measures of glycemic variability are useful in predicting both actual and long-lasting glycemic control. In absence of diabetes-related complications and of any intima-media thickness alterations, the major predictors of arterial distensibility are represented by traditional risk factors beside glycemic 24-h control. © 2013 Scandinavian Foundation for Cardiovascular Researc
The mild oxidation of nitrile oxides affords a convenient entry to nitrosocarbonyl intermediates, versatile tools in organic syntheses
Nitrile oxides are oxidized by tertiary amine N-oxides in different solvents at room temperature to afford in the presence of dienes nitrosocarbonyl adducts in fair yields. The mild conditions used in oxidizing a variety of nitrile oxides promise a wide application of this method in synthetic processes
Cycloaddition of Nitrile Oxide to Amidoximes. A General Synthesis of 3,5-Disubstituted 1,2,4-Oxadiazole-4-oxides
The cycloaddition of nitrile oxides to amidoximes are investigated
A pericyclic cascade in the addition of diphenyl nitrilimine to pyridine
On refluxing in benzene in the presence of excess pyridine the monocycloadduct of diphenyl nitrilimine to pyridine undergoes a [1,5] sigmatropic shift and a subsequent electrocyclic opening to afford 1,2,4-triazole derivatives
Cycloaddition of Benzonitrile Oxide to Pyridazine, Pyrimidine and Pyrazine
Cycloaddition of Benzonitrile Oxide to Pyridazine, Pyrimidine and Pyrazine are investigated
Derivatives of Imidazole. I. Synthesis and Reactions of Imidazo[1,2-α]pyridines with Analgesic, Antiinflammatory, Antipyretic, and Anticonvulsant Activity
Bedside surgery in the newborn infants: survey of the Italian society of pediatric surgery
This is the report of the first official survey from the Italian Society of Pediatric Surgery (ISPS) to appraise the distribution and organization of bedside surgery in the neonatal intensive care units (NICU) in Italy
Bedside surgery in the newborn infants: survey of the Italian society of pediatric surgery
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes